The Contracts Every Pharmaceutical Company Needs (2026 Checklist)

Why a pharmaceutical company needs tight contracts A pharmaceutical company develops, manufactures, and sells regulated products that affect patient safety. It runs clinical trials through outside parties, buys active ingredients, outsources manufacturing, licenses molecules in and out, and reports safety data to regulators. Each of those activities rests on a contract, and because the products are regulated, several of those contracts are themselves conditions of staying compliant. When a trial result is disputed, a supplier fails a quality audit, a licensed product underperforms, or a safety signal is missed, the first question is what was agreed and who carried which duty. Clear contracts answer that before it becomes a regulatory or liability problem. This is a general checklist. The exact documents and wording depend on your country, your regulators, and your products, so use it to find gaps rather than as final advice. ## Research and development contracts Clinical research organisation (CRO) agreement. Governs an outsourced clinical trial: scope, milestones, data ownership, safety reporting, audit rights, regulatory responsibilities, and indemnities. Because the sponsor keeps regulatory accountability, the allocation of duties here is central. Clinical trial agreement with sites and investigators. Between the sponsor and each trial site or investigator, covering the protocol, payment, patient-data handling, publication rights, and liability for trial-related harm. Research collaboration and sponsored-research agreements. With universities and research institutes, where intellectual property ownership, publication, and background-versus-foreground IP are the key terms. Material transfer agreements (MTAs). For sharing compounds, cell lines, or samples with partners, setting permitted use, onward transfer, and IP in results. ## Manufacturing and supply contracts Contract manufacturing (CMO) agreement. For outsourced manufacture of drug substance or product, covering capacity, specifications, pricing, and regulatory responsibilities. Quality or technical agreement. A separate, detailed agreement that sits alongside the CMO or supply contract and allocates good-manufacturing-practice responsibilities, release, deviations, recalls, and audit rights. Regulators expect this document to exist, so it is not optional for outsourced manufacture. Active ingredient and raw-material supply agreements. With API and excipient suppliers, covering specifications, lead times, change control, and continuity of supply. Distribution and wholesaler agreements. With distributors and wholesalers, covering territory, cold-chain and handling duties, returns, and compliance with distribution rules. ## Commercial and licensing contracts In-licensing and out-licensing agreements. The core deals that move a molecule or product between companies, covering upfront and milestone payments, royalties, territory, field of use, diligence obligations, and what happens on termination. These are often a company's most valuable contracts. Co-development and co-promotion agreements. Where two companies share development cost or sales effort, with governance, cost sharing, and profit-split terms. Distribution, agency, and tender agreements. For bringing products to market in different territories, including public-tender and reimbursement considerations. ## Safety, data, and compliance contracts Pharmacovigilance (safety data exchange) agreement. Where more than one party handles a product, a dedicated agreement sets how adverse-event and safety data is exchanged and reported on time. Missing or late safety reporting is a serious regulatory failure, so this document matters a great deal. Data processing and clinical-data agreements. Trials and operations generate personal and health data, so processors need data processing agreements, and clinical data carries additional protection duties. Anti-bribery and interactions-with-healthcare-professionals terms. Interactions with prescribers and institutions are tightly regulated, so consultancy, speaker, and advisory-board agreements need compliant terms and fair-market-value payment. ## People, IP, and corporate contracts Employment and consultant agreements. With strong confidentiality and IP-assignment terms, since the company's value is largely in its know-how and pipeline. Patent licences and IP assignments. The agreements that secure the company's rights in its molecules, formulations, and processes. Premises, equipment, and insurance. Leases for labs and plants, finance for specialist equipment, and product-liability and clinical-trial insurance to track and renew. ## A short checklist to run against your company - Does every outsourced trial have a CRO agreement and site agreements that fix data ownership, safety reporting, and audit rights?

• Is there a signed quality or technical agreement alongside every manufacturing and key supply contract?
• Does every licensing deal clearly set milestones, royalties, territory, diligence, and termination?
• Is there a pharmacovigilance agreement wherever safety data is shared with a partner?
• Do interactions with healthcare professionals run on compliant, fair-market-value agreements?
• Are IP assignments, data processing agreements, and product-liability insurance all current and tracked? ## Keeping the company's contracts in one place Pharmaceutical companies run hundreds of interlocking agreements where a single missed milestone, audit right, or safety-reporting duty can become a regulatory finding. Too often these sit across business-development folders, a quality team's drives, and outside counsel's email, with no one able to answer quickly which quality agreements are overdue for review or which licences carry a diligence deadline next quarter. Drafting these documents, reviewing them for risky terms, tracking obligations and renewal dates, and keeping a clean version history is really one connected job, and it is far easier when it lives in a single place. That one-workspace idea is what Adira is built around for business contracts, with per-clause risk visible and a built-in activity history, drafting and review running on Claude. Whatever tool you use, the checklist above holds: the companies that stay out of trouble are the ones whose contract discipline matches their quality discipline. ## An honest note Pharmaceutical regulation, good-manufacturing-practice and good-clinical-practice requirements, pharmacovigilance duties, anti-bribery rules, and data protection all vary by country and regulator and change often. Treat this as a map of what to have in place, then have the specific documents drafted or reviewed by qualified regulatory and legal advisers for your products and markets. This is general information, not legal advice.